

THERAVECTYS SECURES EXCLUSIVE ACCESS TO A SYNTHETIC HUMANIZED NANOBODY LIBRARY FROM INSTITUT CURIE AND STRENGTHENS ITS PROPRIETARY IMMUNOTHERAPEUTIC PLATFORM

PARIS, April 14th, 2015

THERAVECTYS, a pioneer in the development of lentiviral vector therapeutic vaccines and T-cell therapies, announced today its exclusive license to a library of synthetic humanized camelid nanobodies, developed at the Institut Curie in Paris, France.

Over the last 10 years, THERAVECTYS has continuously strengthened its **in-house expertise in lentiviral vectors** and searched to demonstrate synergies with **other innovative and complementary immunotherapy approaches**. These efforts have led to evidence of **sustainable remissions in cancer** and the **durable treatment of major global infectious diseases**.

With the addition of the **nanobody synthetic library from the Institut Curie**, THERAVECTYS now owns **one of the most comprehensive immunotherapeutic platforms** able to stimulate and modulate the immune system: **prophylactic & therapeutic vaccines** (through the direct administration of lentiviral vectors), **Chimeric Antigen Receptor (CAR) & T Cell Receptor (TCR)** based cell therapies and **anti-checkpoint inhibitors**, along with additional strategic assets.

Under the terms of the agreement, THERAVECTYS has acquired **exclusive worldwide rights to the library** to:

- Generate proprietary receptors for CAR & TCR-based therapies
- Identify checkpoint inhibitors
- Screen tumor antigens

In addition to the licensing agreement, THERAVECTYS and the Institut Curie have entered into a **long-term R&D alliance**, in order to optimize the library and accelerate the development of THERAVECTYS' ongoing **programs in immuno-oncology**. The synthetic nature of the library will allow the **identification of nanobodies in less than six months**, as well as the engineering of their biochemical properties including affinity and stability.

"Our nanobody library offers an unrivalled potential in immuno-oncology. The low molecular weight of nanobodies allow their insertion into lentiviral vectors and can thus be expressed as CARs on T and NK cells," said **Frank PEREZ**, Research Director at the Institut Curie and at the Centre National de la Recherche Scientifique (CNRS).

"We are pleased to collaborate with THERAVECTYS. I am convinced that the intense and long-lasting immune responses induced by their lentiviral vector vaccines, combined with the tumor de-protection effect of our anti-checkpoint nanobodies, will change the game in the immuno-oncology field and further improve the current immunotherapy-based treatments in cancer," commented **Sebastian AMIGORENA**, Director of INSERM Unit 932 at Institut Curie.

About THERAVECTYS

THERAVECTYS is a privately-owned, fully-integrated discovery and clinical development biotech company originating from the Pasteur Institute.

The company capitalizes on over 15 years of fundamental research in the field of lentiviral vectors and has secured worldwide exclusive rights to Pasteur Institute intellectual property.

Based on its lentiviral vector technology platform, THERAVECTYS develops therapeutic vaccines and immunotherapies to fight cancers and infectious diseases, including a proprietary

and differentiated CAR T-cell technology platform.

The company is strongly supported by renowned investors and former global biopharmaceutical executives and is rapidly progressing in its R&D activities and in-house GMP production capabilities.

Alone and in collaboration with partners, THERAVECTYS is accelerating its clinical development programs and is planning to initiate two additional phase I/II clinical trials in oncology in 2015.

For more information:

Abhishek BASU

+1 646 722 8820 - abasu@healthstarpr.com



THERAVECTYS - Villejuif BioPark, 1 Mail du Professeur Georges Mathé 94800 VILLEJUIF, FRANCE - SARL Capital: 147 356,20 EUR

www.theravectys.com